Pharmacokinetics, Pharmacodynamics, and Toxicology Aspects of Immunotherapeutics
Author:
Kulkarni PreetiORCID,
Mehta Parsshava,
Shriyan Bharati,
Gawit Kalpita,
Gota Vikram,
Ghante MinalORCID
Publisher
Springer Singapore
Reference73 articles.
1. Agrawal S, Feng Y, Roy A, Kollia G, Lestini B (2016) Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy. J Immunother Cancer 4:72
2. Ahamadi M, Freshwater T, Prohn M, Li CH, de Alwis DP, de Greef R et al (2017) Model-based characterization of the pharmacokinetics of pembrolizumab: a humanized anti-PD-1 monoclonal antibody in advanced solid tumors. CPT Pharmacometrics Syst Pharmacol 6(1):49–57
3. Arenberger P, Fialova A, Gkalpakiotis S, Pavlikova A, Puzanov I, Arenbergerova M (2017) Melanoma antigens are biomarkers for ipilimumab response. J Eur Acad Dermatol Venereol 31(2):252–259
4. Bajaj G, Wang X, Agrawal S, Gupta M, Roy A, Feng Y (2017) Model-based population pharmacokinetic analysis of nivolumab in patients with solid tumors. CPT Pharmacometrics Syst Pharmacol 6(1):58–66
5. Bajaj G, Suryawanshi S, Roy A, Gupta M (2019) Evaluation of covariate effects on pharmacokinetics of monoclonal antibodies in oncology. Br J Clin Pharmacol 85(9):2045–2058